RSF1 amplification and relapse-free survival.

RFS for patients with RSF1 gene amplification or not, showing benefit from tamoxifen in both groups. Kaplan-Meier curves for RFS, tamoxifen vs. placebo in patients with RSF1 gene non-amplified (“low RSF1”) (A) and amplified (“high RSF1”) (B) tumors. Adjusted HRs are included for the comparison of tamoxifen vs. placebo in each group.



CC BY 4.0